Lilly(Eli) & Co

NYSE:LLY   3:59:58 PM EDT
244.90
+1.15 (+0.47%)
Products

FDA Authorizes Bamlanivimab And Etesevimab Monoclonal Antibody Therapy For Post-Exposure Prophylaxis (Prevention) For Covid-19

Published: 09/16/2021 19:19 GMT
Lilly(Eli) & Co (LLY) - FDA Authorizes Bamlanivimab and Etesevimab Monoclonal Antibody Therapy for Post-exposure Prophylaxis (prevention) for Covid-19.
FDA -revised Eua for Bamlanivimab and Etesevimab to Include Emergency Use As Post-exposure Prophylaxis for Covid-19 in Patients at High Risk for Progression to Severe Covid-19.
FDA - Post-exposure Prophylaxis With Bamlanivimab and Etesevimab, Administered Together, is Not a Substitute for Vaccination Against Covid-19.
FDA - Bamlanivimab and Etesevimab, Administered Together, Authorized for Use After Exposure to Virus.
FDA - Bamlanivimab and Etesevimab, Administered Together, Not Authorized for Pre-exposure Prophylaxis to Prevent Covid-19 Before Being Exposed to Sars-cov-2 Virus.
Further Company Coverage: Llyn ((reuters.
Briefs@thomsonreuters.
Com;)).